Argenx price target raised to $640 from $500 at JPMorgan

JPMorgan analyst James Gordon raised the firm’s price target on Argenx to $640 from $500 and keeps an Overweight rating on the shares. The analyst sees Vyvgart beating consensus expectations in 2025, driven by the chronic inflammatory demyelinating polyneuropathy launch, and also sees teens profitability being delivered in 2025. With further Vyvgart upgrades to come in 2025, along with Argenx reaching strong operating profitability, JPMorgan expect continued share outperformance, the analyst tells investors in a research note.